Cannabis ETFs Rally on Trump Rescheduling Expectations

Cannabis exchange-traded funds are experiencing significant inflows as investors anticipate President Trump's administration will accelerate federal marijuana rescheduling efforts. The AdvisorShares Pure US Cannabis ETF (MSOS) and ETFMG Alternative Harvest ETF (MJ) have both posted double-digit gains over the past month, reflecting growing institutional confidence in regulatory reform momentum.

The market optimism stems from Trump's campaign promises to support rescheduling marijuana from Schedule I to Schedule III, a move that would reduce federal tax burdens on cannabis operators and potentially unlock interstate commerce. This regulatory shift could eliminate the 280E tax provision that currently prevents cannabis companies from deducting standard business expenses, immediately improving profit margins across the sector.

Institutional investors are increasingly viewing cannabis ETFs as the preferred vehicle for sector exposure, given the compliance complexities of directly holding individual cannabis stocks. MSOS, which focuses exclusively on U.S. multi-state operators, has attracted particular attention as it provides diversified exposure to companies that would benefit most from federal reform. The fund's top holdings include major operators positioned for interstate expansion once federal barriers fall.

The rescheduling catalyst comes at a critical time for cannabis operators, many of which trade at significant discounts to traditional retail and consumer goods companies despite generating comparable revenue growth. Federal reform could trigger a sector-wide rerating as institutional investors gain clearer regulatory pathways for cannabis investments.

While rescheduling momentum builds, investors remain focused on the timeline and implementation details. The Drug Enforcement Administration's review process continues, but political pressure from the incoming administration could accelerate decision-making. Cannabis ETFs offer investors immediate exposure to this regulatory arbitrage opportunity while maintaining portfolio diversification across the fragmented U.S. cannabis market.